Overview

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Status:
Recruiting
Trial end date:
2023-02-26
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Nektar Therapeutics